Physician

Felipe Rosso, M.D.

According to 2025 Medicare claims, Felipe Rosso, M.D. (NPI: 1538332788) practices urology in the Manhattan, KS market, with the plurality of this provider's patient population coming from Riley, KS. This provider's primary affiliated billing organization is ASSOCIATED UROLOGISTS, PA (NPI: 1760453674; TIN: 480894157) and primary practice location at 66502-2756. Rosso is affiliated with the NPG Health Collaborative LLC (ACO ID: A3287) and Vytalize Health KS 25 LLC (ACO ID: A5671), participating under the MSSP model.

Rosso's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 916 traditional Medicare patients, billed 2,491 HCPCS/CPT codes, and received $229,168 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,409 prescription claims across 385 beneficiaries totaling $991,449 in drug costs, led by Xtandi (Enzalutamide). DME data shows 156 claims. Open Payments data shows 47 records totaling $801. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $127,944 to $229,168. Similarly, Part D prescription costs have moved sharply higher in recent years, from $24,028 to $991,449. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $545 to $219.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	488	7,277	$127,944
2016	523	18,782	$116,874
2017	610	12,101	$135,756
2018	621	8,022	$147,270
2019	705	11,170	$174,977
2020	647	8,731	$157,604
2021	702	20,026	$194,357
2022	878	7,819	$216,332
2023	984	10,329	$215,125
2024	916	2,491	$229,168

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	183	561	$24,028
2016	186	638	$28,971
2017	181	779	$46,830
2018	217	786	$65,591
2019	244	820	$61,861
2020	234	904	$71,732
2021	280	943	$82,265
2022	297	1,012	$99,986
2023	333	1,197	$591,225
2024	385	1,409	$991,449

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	57	$7,747
2016	N/R	119	$26,337
2017	N/R	120	$27,315
2018	N/R	134	$29,389
2019	N/R	171	$30,287
2020	N/R	193	$18,961
2021	N/R	114	$14,499
2022	N/R	189	$20,502
2023	12	198	$22,716
2024	13	156	$27,392

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	216	248	$86
99203	New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more	114	114	$68
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	294	362	$60
52000	Diagnostic exam of bladder and urethra using an endoscope	159	196	$57
99212	Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more	238	272	$32

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	39	1,170	$550,056
Abiraterone Acetate	Abiraterone Acetate	12	360	$95,505
Orgovyx	Relugolix	33	990	$88,765
Myrbetriq	Mirabegron	98	4,054	$60,538
Gemtesa	Vibegron	104	3,208	$52,790

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4351	Intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, silicone elastomer, or hydrophilic, etc.), each	N	13	110	$26,651
A4358	Urinary drainage bag, leg or abdomen, vinyl, with or without tube, with straps, each	N	N/R	19	$454
A4332	Lubricant, individual sterile packet, each	N	N/R	14	$159
A4333	Urinary catheter anchoring device, adhesive skin attachment, each	N	N/R	13	$128

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	47	$801	Sumitomo Pharma America, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Felipe Rosso, M.D.?

Tedicare shows public-source Medicare data for Felipe Rosso, M.D. (NPI 1538332788), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Felipe Rosso, M.D. have ACO affiliation data?

Felipe Rosso, M.D. is shown with ACO affiliation data for NPG Health Collaborative LLC (MSSP, ACO ID A3287) and Vytalize Health KS 25 LLC (MSSP, ACO ID A5671).

What billing organization is linked to Felipe Rosso, M.D.?

Felipe Rosso, M.D. is linked to ASSOCIATED UROLOGISTS, PA (billing NPI 1760453674) in the available physician profile data.

Does Felipe Rosso, M.D. have Open Payments data?

Felipe Rosso, M.D. has 47 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.